AtaiBeckley Inc (NASDAQ:ATAI) is among the best psychedelic stocks to buy in 2026. On March 17, AtaiBeckley Inc (NASDAQ:ATAI) ...

AtaiBeckley (NasdaqGM:ATAI) reported positive, peer reviewed Phase 2a results for its lead psychedelic drug BPL-003 in treatment resistant depression. The company received supportive FDA feedback for ...

AtaiBeckley is a clinical-stage psychedelic biotech targeting TRD and SAD, with BPL-003 as its lead value driver. Learn more ...

Atai Life Sciences (ATAI) this past Friday, July 25, 2025 reported results from its phase 2b study using its drug inidascamine for the treatment of patients with cognitive impairment associated with ...

NEW YORK and BERLIN, Jan. 04, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ...

Atai Life Sciences (NASDAQ:ATAI) is one of the best multibagger penny stocks to buy according to analysts. On July 29, Oppenheimer initiated coverage of the stock with an ‘Outperform’ rating and a $14 ...

Atai Life Sciences N.V. (NASDAQ:ATAI) is one of the best healthcare penny stocks to buy now. On September 15, H.C. Wainwright reiterated a ‘Buy’ rating on the stock and a $15 price target. The ...

This biopharma play with two key drugs for treatment-resistant depression could see its stock rise by more than 230%, ...

Depression remains one of the world’s most debilitating conditions, impacting millions worldwide with symptoms that can disrupt every facet of life — from work and relationships to basic daily ...

ATAI Life Sciences, a biopharmaceutical company aiming to make psychedelic drugs to treat mental health disorders, announced that it is planning to raise $100 million in an initial public offering.

NEW YORK and AMSTERDAM, Oct. 20, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) ("atai"), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health ...